Narayana Hrudayalaya Ltd — Stock Report

Narayana Hrudayalaya, operating under the Narayana Health brand, is a leading healthcare services company with a network of 18 multispecialty hospitals and 2 dedicated heart centers in India, plus an international presence in the Cayman Islands. It runs over 5,550 operational beds and is known for its high-volume, cost-efficient care model, especially in cardiac and critical care. Financially, the company has shown solid growth. In FY 2025, its consolidated revenue rose ~12.1% to ₹54,830 million, while PAT was ₹7,898 million — essentially flat YoY, reflecting stable profits. Net debt remains very low (net debt-to-equity ~0.15), giving it financial flexibility. EBITDA margins have expanded, with Q4 FY25 hitting ~26.1%. In Q1 FY25, the company reported revenue of ₹13,410 million and a PAT margin of ~15%. In its most recent Q2 FY26 results, revenue jumped 20.3% YoY to ₹16,438 million, EBITDA rose ~28% with a 25.9% margin, and PAT surged ~30% YoY to ₹2,583 million. Its strengths include scale, brand strength, and a dual geography model — strong domestic operations combined with Cayman-based facilities that generate dollar-denominated revenues, boosting its resilience. The company also continues to expand its integrated care business through outpatient clinics, and benefits from operating leverage and a strong payor mix. On the risk side, healthcare is capital intensive; hospitals need heavy capex, and running costs are high. Though debt is low now, future expansions may increase leverage. Volume growth is lumpy, and regulatory or reimbursement risk (insurance, government payors) remains. International business adds currency and operational risk. Also, execution of growth (new hospitals, clinics) must be closely watched.